Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.

[1]  R. Fontana,et al.  Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B , 2013, Alimentary pharmacology & therapeutics.

[2]  A. Moorman,et al.  Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Kenta Yamamoto,et al.  Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. , 2013, Journal of hepatology.

[4]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[5]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[6]  M. Volk,et al.  A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[8]  V. Wong,et al.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis , 2013, Hepatology.

[9]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[10]  T. Wilt,et al.  Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference , 2009, Annals of Internal Medicine.

[11]  R. D. de Man,et al.  Peg‐interferon improves liver histology in patients with HBeAg‐positive chronic hepatitis B: no additional benefit of combination with lamivudine , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[12]  V. Wong,et al.  44 PERFORMANCE OF HEPATOCELLULAR CARCINOMA RISK SCORES IN CHRONIC HEPATITIS B PATIENTS RECEIVING ENTECAVIR TREATMENT , 2013 .

[13]  D. Harnois.  Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease , 2009 .

[14]  Peter C Austin,et al.  The performance of different propensity-score methods for estimating relative risks. , 2008, Journal of clinical epidemiology.

[15]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[16]  M. Sherman.  Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma? , 2013, Hepatology.

[17]  J. Ward,et al.  Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Jaw-Town Lin,et al.  Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. , 2012, JAMA.

[19]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[20]  L. Rodrigo,et al.  Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis , 2003, Hepatology.

[21]  Ching-Lung Lai,et al.  Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy , 2013, Hepatology.